Global pharmaceutical industry news that goes beyond the headlines

From licensing and clinical trials to competitor activity, stay current on business developments in your market.

Scrip delivers high-value commercial intelligence and analysis on the latest licensing opportunities, partnership deals, R&D activity, company developments and market access insights — providing all you need to understand the potential impact of market developments on your business.

Timely and tactical decision-making throughout the entire drug discovery, development and product life cycle value chain, empowers you to make more informed decisions faster — so you accelerate time to market, realize greater cost savings and stay ahead of the competition.

Industry news and insights

How it helps

Use Scrip’s focus on the strategic implications of global pharma news to fully understand what worldwide developments in the industry mean for your business.

With end-to-end coverage encompassing the whole of the drug discovery, development and product life cycle value chain, Scrip delivers analysis, news and insights across multiple therapy areas and product types.

Professionals accessing Scrip for the latest industry news and developments to gain advantage on competition.

How it works

Make the right decisions for the long-term, backed by expert data, analysis and insight, robust interactive tools and expertise on call.

  • Company news in context: what industry developments really mean for strategy, next steps and the competitive landscape.
  • Pipeline Watch: R&D progress for essential competitor data and drug strategy development
  • Emerging Company Profiles: leading-edge companies exploring new trends and technologies
  • M&A and Deals: in-depth analysis and round ups of partnerships, licensing and acquisitions across the biopharma sector
  • Trend Spotting: in-market access, pipeline reviews, and more
  • Executive Interviews: with key opinion leaders, decision-makers and industry experts
  • Exclusive Market Forecasts: using Citeline proprietary databases including Datamonitor Healthcare, Biomedtracker, Pharmapremia and more
  • Financing: comprehensive analysis of venture funding, public offerings and start-up financing
What's included
Uncover current market dynamics 

Assess information including successful and at-risk drug classes, market opportunity, threat of substitution and payer pressure.

Insight beyond the headlines

Understand the strategic implications of global commercial pharma news and their potential impact on your business.

Unparalleled access to data and decision-makers 

Gain access to best-in class proprietary data as well as exclusive insight from industry leaders.

Powerful digital platform 

Enjoy robust search functionality and the ability to create custom email alerts.

Understand more about how our solutions can help you gain a competitive advantage
Our experts
Citeline’s award-winning publications provide in-depth coverage of the pharmaceutical industry, thanks to 65 in-house journalists who tackle the tough issues with precision, persistence and passion.

We provide comprehensive industry news, on areas ranging from pharmaceutical regulation and policy to generics and the medtech industry.

Our 300+ analysts are trusted advisers to a broad spectrum of the industry, including biopharma, biotechs, financial and professional services, CDMOs and CROs.
A person typing on a keyboard.
A person looking at a screen. Two people in business suits talking.

Related resources

a woman sitting at a table talking to a doctor
JUN 14, 2023

Patient Voice to Data: How Novartis Is Listening Up, Harnessing RWE in APMA

Novartis APAC President Iris Zemzoum says Novartis is empowering patients and also partnering across the diverse region to leverage real-world evidence.

A man in a laboratory coat observing in a microscope
JUL 03, 2023

Quick Listen: Scrip's Five Must-know Things

Join us for an audio catch-up on the major events in the biopharma industry over the past business week.

OCT 01, 2023

Idorsia, Still Facing Cash Crunch, Says Cost-Reduction Effort Will Conclude in 2023

With a commercial product ramping up and three Phase III candidates, Idorsia is burning through cash and needs help beyond its 475-person staff reduction.

Speak to a Specialist
A specialist is ready to help find the solutions that are right for you.
Professionals submitting a form to find out more about Citeline.

Citeline may contact you about relevant products, services and content. To opt-out of these communications or to manage what you receive, please visit our Preference Center.

Your information will be used in accordance with our Privacy notice.